BE2017C049I2 - - Google Patents

Download PDF

Info

Publication number
BE2017C049I2
BE2017C049I2 BE2017C049C BE2017C049C BE2017C049I2 BE 2017C049 I2 BE2017C049 I2 BE 2017C049I2 BE 2017C049 C BE2017C049 C BE 2017C049C BE 2017C049 C BE2017C049 C BE 2017C049C BE 2017C049 I2 BE2017C049 I2 BE 2017C049I2
Authority
BE
Belgium
Application number
BE2017C049C
Original Assignee
Wyeth Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29401497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2017C049(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Holdings Llc filed Critical Wyeth Holdings Llc
Publication of BE2017C049I2 publication Critical patent/BE2017C049I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
BE2017C049C 2002-05-02 2017-11-16 BE2017C049I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37744002P 2002-05-02 2002-05-02
EP03724432.4A EP1507556B1 (fr) 2002-05-02 2003-05-02 Conjugues de type vecteur-derive de calicheamicine

Publications (1)

Publication Number Publication Date
BE2017C049I2 true BE2017C049I2 (fr) 2022-08-09

Family

ID=29401497

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2017C049C BE2017C049I2 (fr) 2002-05-02 2017-11-16

Country Status (33)

Country Link
US (6) US8153768B2 (fr)
EP (3) EP2371392B1 (fr)
JP (5) JP5153057B2 (fr)
KR (2) KR101062628B1 (fr)
CN (1) CN100482277C (fr)
AU (2) AU2003231293A1 (fr)
BE (1) BE2017C049I2 (fr)
BR (3) BR122019027966B8 (fr)
CA (2) CA2483552A1 (fr)
CR (3) CR7557A (fr)
CY (4) CY1116634T1 (fr)
DK (3) DK1507556T3 (fr)
EC (1) ECSP045445A (fr)
ES (3) ES2916174T3 (fr)
FR (1) FR17C1054I2 (fr)
HU (4) HUE030806T2 (fr)
IL (2) IL164946A (fr)
LT (3) LT1507556T (fr)
LU (1) LUC00044I2 (fr)
MX (1) MXPA04010792A (fr)
NL (1) NL300903I2 (fr)
NO (3) NO339730B1 (fr)
NZ (2) NZ573563A (fr)
PH (2) PH12013501158B1 (fr)
PL (5) PL224001B1 (fr)
PT (3) PT3127553T (fr)
RU (3) RU2422157C3 (fr)
SG (3) SG187991A1 (fr)
SI (3) SI1507556T1 (fr)
TW (2) TWI438010B (fr)
UA (1) UA88599C2 (fr)
WO (1) WO2003092623A2 (fr)
ZA (2) ZA200409752B (fr)

Families Citing this family (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US20110045005A1 (en) * 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
DK1507556T3 (en) 2002-05-02 2016-09-12 Wyeth Holdings Llc Calicheamicin derivative-carrier conjugates
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
TW200539855A (en) * 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
EP1759582B1 (fr) * 2004-05-26 2016-11-23 National University Corporation Kagawa University Solution de conservation pour cellules, tissus et organes comprenant un sucre rare et procede de conservation faisant usage de celle-ci
TW200621282A (en) * 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
AU2004224925C1 (en) * 2004-08-30 2011-07-21 Biotest Ag Immunoconjugates targeting syndecan-1 expressing cells and use thereof
CN101035564A (zh) * 2004-09-10 2007-09-12 惠氏公司 人源化的抗5t4抗体和抗5t4抗体/加利车霉素缀合物
EP1661584A1 (fr) * 2004-11-26 2006-05-31 Heinz Dr. Faulstich Application de conjuguées d' amatoxines et de phallotoxines avec des macromolécules pour la thérapie du cancer et de l'Inflammation
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US20070003559A1 (en) * 2005-07-01 2007-01-04 Wyeth Methods of determining pharmacokinetics of targeted therapies
AU2006279891B2 (en) 2005-08-16 2010-03-11 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) formulation
AU2006283726C1 (en) 2005-08-24 2015-05-07 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
ES2564241T3 (es) * 2005-12-02 2016-03-21 Glaxosmithkline Biologicals Sa Nanopartículas para su uso en composiciones inmunogénicas
BRPI0619476A2 (pt) * 2005-12-05 2011-10-04 Wyeth Corp composições de interleucina-11 e métodos de uso
CA2645097C (fr) 2006-03-10 2019-09-17 Wyeth Anticorps anti-5t4 et leurs utilisations
ES2371085T3 (es) * 2006-05-27 2011-12-27 Faulstich, Heinz, Dr. Utilización de conjugados de amatoxinas o falotoxinas con macromoléculas para la terapia tumoral y de la inflamación.
DK3255141T3 (da) 2006-07-13 2022-01-31 Wyeth Llc Fremstilling af antistoffer med forbedret glycosyleringsmønster
JP2010501562A (ja) 2006-08-21 2010-01-21 シンタ ファーマシューティカルズ コーポレーション 増殖性障害を治療するための化合物
BRPI0719250A2 (pt) * 2006-10-12 2015-06-16 Wyeth Corp Métodos e composições com opalescência reduzida.
EP2395077A1 (fr) 2006-11-03 2011-12-14 Wyeth LLC Substances inhibant la glycolyse dans une culture de cellules
BRPI0717902A2 (pt) 2006-12-01 2013-10-29 Medarex Inc "anticorpo monoclonal humano isolado, composição, conjugado anticorpo-molécula parceria, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para prepar um anticorpo anti-cd22, método para inibir o desenvolvimento de uma célula tumoral que expressa cd22 e método para tratar uma doença inflamatória ou autoimuneem um indivíduo"
US8552067B2 (en) * 2006-12-22 2013-10-08 The Regents Of The University Of California Macromolecular conjugates of cystic fibrosis transmembrane conductance regulator protein inhibitors and uses therefor
MX2009007368A (es) * 2007-01-16 2009-07-16 Wyeth Corp Deteccion, tratamiento y monitoreo de la inflamacion, por medio del receptor de disparo expresado en la celula 1 mieloide (trem-1).
JP5586235B2 (ja) * 2007-03-02 2014-09-10 ワイス・エルエルシー ポリペプチドの産生のための細胞培養における銅およびグルタミン酸塩の使用
CA2687852A1 (fr) 2007-05-22 2008-12-04 Wyeth Procedes ameliores de fabrication d'hydrazides
PE20090309A1 (es) * 2007-06-04 2009-04-18 Wyeth Corp Conjugado portador-caliqueamicina y un metodo de deteccion de caliqueamicina
DK2211904T3 (en) * 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
AU2008342956A1 (en) * 2007-12-21 2009-07-09 Genentech, Inc. Therapy of rituximab-refractory rheumatoid arthritis patients
BRPI0821447A2 (pt) * 2007-12-26 2015-06-16 Biotest Ag Anticorpo de alvejamento engenheirado, composição farmacêutica, hibridoma, ensaio com base em anticorpo, polipeptídeo isolado, e, método para ligação homogênea
CN101945892B (zh) * 2007-12-26 2017-11-24 生物测试股份公司 用于改进对表达cd138的肿瘤细胞的靶向的方法和试剂
WO2009080831A1 (fr) * 2007-12-26 2009-07-02 Biotest Ag Procédé permettant de réduire les effets secondaires cytotoxiques et d'améliorer l'efficacité des immunoconjugués
DK2242772T3 (en) * 2007-12-26 2015-01-05 Biotest Ag Immunoconjugates that targets CD138, and uses thereof
US20090186026A1 (en) * 2008-01-18 2009-07-23 Wyeth Ephrin and eph receptor agonists for modulation of bone formation and resorption
US8591889B2 (en) 2008-04-04 2013-11-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies specific for CD22
FR2930443B1 (fr) 2008-04-29 2010-06-25 Oreal Produit extemporane de soin a base d'un lyophilisat de microorganisme et de tensioactif(s) de hlb superieur ou egal a 12
HUE034763T2 (en) 2008-04-30 2018-02-28 Immunogen Inc Crosslinkers and their use
MX2011012794A (es) * 2009-06-03 2012-05-08 Immunogen Inc Metodos de conjugacion.
WO2011098518A2 (fr) * 2010-02-11 2011-08-18 Ablynx Nv Administration de domaines variables d'immunoglobuline et de produits de construction de ceux-ci
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012023085A1 (fr) 2010-08-20 2012-02-23 Wyeth Llc Culture cellulaire de cellules adaptées exemptes de facteur de croissance
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
EP2637692A4 (fr) 2010-11-12 2014-09-10 Scott & White Healthcare Anticorps contre le marqueur 8 endothélial tumoral
US20120222979A1 (en) * 2011-03-04 2012-09-06 Elwha LLC, a limited liability company of the State of Delaware Glassy compositions
ME03353B (fr) 2011-03-29 2019-10-20 Immunogen Inc Préparation de conjugués de maytansinoïde anticorps par procédé en une étape
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
HUE042327T2 (hu) 2011-08-30 2019-06-28 Astex Pharmaceuticals Inc Decitabin-származék készítmények
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
KR20140077977A (ko) 2011-10-21 2014-06-24 화이자 인코포레이티드 철을 첨가하여 세포 배양을 개선하는 방법
CN104302324A (zh) 2011-12-08 2015-01-21 生物测试股份公司 靶向cd138的免疫偶联物的用途
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2834259A4 (fr) 2012-04-02 2016-08-24 Moderna Therapeutics Inc Polynucléotides modifiés
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
SG10201913370PA (en) 2012-07-03 2020-03-30 Univ Washington Antibodies to tau
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
WO2014055877A1 (fr) 2012-10-04 2014-04-10 Immunogen, Inc. Utilisation d'une membrane de pvdf pour purifier des conjugués d'agent de liaison cellulaire-agent cytotoxique
CA2891280C (fr) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Lieurs hydrophiles et leurs utilisations pour la conjugaison de medicaments a des molecules se liant aux cellules
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
AR094280A1 (es) 2012-12-21 2015-07-22 Bioalliance Cv Enlazantes hidrofilicos auto-inmolantes y conjugados de los mismos
WO2014113203A1 (fr) 2013-01-17 2014-07-24 Case Western Reserve University Multimères de nanoparticules virales
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
ES2693370T3 (es) * 2013-05-02 2018-12-11 F. Hoffmann-La Roche Ag Politerapia de un anticuerpo CD20 afucosilado con un conjugado de anticuerpo CD22-fármaco
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (fr) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucléotides codant pour un récepteur de lipoprotéines de faible densité
CA3131631A1 (fr) * 2013-11-04 2015-05-07 Pfizer Inc. Intermediaires et procedes de synthese de drives de la calicheamicine
WO2015065954A1 (fr) 2013-11-04 2015-05-07 Pfizer, Inc. Conjugués anticorps anti-efna4-médicament
CN106414465B (zh) 2014-02-28 2021-11-16 杭州多禧生物科技有限公司 带电荷链接体及其在共轭反应上的应用
ES3005909T3 (en) 2014-03-19 2025-03-17 Pfizer Method of cell culture
US11998594B2 (en) 2014-04-02 2024-06-04 Case Western Reserve University Anti-cancer plant virus particles linked to HER2 antigens
MX2016016490A (es) 2014-06-20 2017-07-28 Bioalliance Cv Conjugados de farmaco-anticuerpo anti-receptor de folato alfa (fra) y metodos de uso de los mismos.
TWI664190B (zh) 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
US9925281B2 (en) 2014-08-05 2018-03-27 Case Western Reserve University Coated plant virus imaging agents
WO2016073972A1 (fr) 2014-11-07 2016-05-12 Case Western Reserve University Immunothérapie du cancer utilisant des particules virales
US12465624B2 (en) 2018-05-08 2025-11-11 Case Western Reserve University Cancer immunotherapy using virus particles and immune checkpoint therapy
AU2016246737B2 (en) 2015-04-07 2019-11-21 Cornell University Nanoparticle immunoconjugates
US20180133337A1 (en) * 2015-04-21 2018-05-17 Abbvie Stemcentrx Llc Calicheamicin constructs and methods of use
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
ES2889906T3 (es) 2015-05-21 2022-01-14 Harpoon Therapeutics Inc Proteínas de unión triespecíficas y usos médicos
EP3313527B1 (fr) 2015-06-29 2021-02-24 Case Western Reserve University Particules de virus de plantes contenant un médicament anticancéreux
US10485764B2 (en) 2015-07-02 2019-11-26 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
NZ739830A (en) 2015-07-12 2021-12-24 Hangzhou Dac Biotech Co Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
WO2017011826A1 (fr) * 2015-07-16 2017-01-19 Case Western Reserve University Particules de phytovirus pour l'administration d'agents antimitotiques
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
EP4446338A3 (fr) 2015-09-23 2025-05-07 Pfizer Inc. Cellules et procédé de culture cellulaire
JP2018536404A (ja) 2015-11-09 2018-12-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｈｏ細胞において産生したポリペプチドの品質特性を操作する方法
RU2766000C2 (ru) 2016-01-08 2022-02-07 АльтруБио Инк. Четырехвалентные антитела к psgl-1 и их применения
US20170281758A1 (en) * 2016-03-29 2017-10-05 Sorrento Therapeutics, Inc. Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin
HRP20241328T1 (hr) 2016-04-05 2024-12-20 Pfizer Inc. Postupak kulture stanica
CA3024723A1 (fr) 2016-05-20 2017-11-23 Robert B. Dubridge Proteine de liaison a l'albumine serique a domaine unique
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
EP3487527A4 (fr) 2016-07-21 2020-03-11 Case Western Reserve University Structures de particules de virus végétal ou de type viral
CA3042695A1 (fr) 2016-11-03 2018-05-11 Case Western Reserve University Constructions de nanoparticules virales traitees par fusion
US12433840B2 (en) 2016-11-03 2025-10-07 Case Western Reserve University Melt processed viral nanoparticle constructs
CN116143678A (zh) 2016-11-14 2023-05-23 杭州多禧生物科技有限公司 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用
US11590183B2 (en) 2017-03-10 2023-02-28 Case Western Reserve University Cancer immunotherapy using virus particles
WO2018167621A1 (fr) 2017-03-16 2018-09-20 Pfizer Inc. Prototrophie à la tyrosine
BR112019023855B1 (pt) 2017-05-12 2021-11-30 Harpoon Therapeutics, Inc Proteínas de ligação à mesotelina
US11672840B2 (en) 2017-05-17 2023-06-13 Case Western Reserve University Anticancer trail-targeted plant virus particles
CN111182908A (zh) 2017-08-03 2020-05-19 大塚制药株式会社 药物化合物及其纯化方法
WO2019055796A1 (fr) 2017-09-15 2019-03-21 Bristol-Myers Squibb Company Surveillance de capacité de biomasse en ligne pendant la production à grande échelle de polypeptides d'intérêt
JP7084990B2 (ja) 2017-10-13 2022-06-15 ハープーン セラピューティクス，インク． 三重特異性タンパク質と使用方法
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
WO2019084555A1 (fr) 2017-10-27 2019-05-02 Case Western Reserve University Virus tymovirus et particules de type viral utiles en tant que nanovecteurs pour l'imagerie et agents thérapeutiques
JP7462566B2 (ja) 2018-03-16 2024-04-05 ブリストル－マイヤーズ スクイブ カンパニー タンパク質生産の間の代謝酵素活性およびジスルフィド結合還元
CN110507824A (zh) * 2018-05-21 2019-11-29 荣昌生物制药（烟台）有限公司 一种抗间皮素抗体及其抗体药物缀合物
RU2770474C1 (ru) * 2018-05-30 2022-04-18 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Конъюгаты антитело к sez6-лекарственное средство и способы применения
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN113286817B (zh) 2018-09-25 2025-01-28 哈普恩治疗公司 Dll3结合蛋白及使用方法
EP3883610A4 (fr) 2018-11-20 2022-11-02 Cornell University Complexes macrocycliques de radionucléides et leur utilisation en radiothérapie du cancer
CA3121884A1 (fr) 2018-12-06 2020-06-11 Pfizer Inc. Cellules a production reduite d'inhibiteurs et procedes d'utilisations correspondants
CA3127142A1 (fr) * 2019-02-13 2020-08-20 Coimmune, Inc. Immunotherapie anticancereuse utilisant des combinaisons de cellules exprimant des recepteurs d'antigenes chimeriques et des anticorps monoclonaux
EP3941503A1 (fr) 2019-03-19 2022-01-26 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Polythérapie à l'aide d'omomyc et d'un anticorps se liant à pd-1 ou ctla-4 pour le traitement du cancer
US11390853B2 (en) 2019-04-26 2022-07-19 Case Western Reserve University Freeze dried viral nanoparticle constructs
CA3146379A1 (fr) * 2019-07-08 2021-01-14 Mythic Therapeutics, Inc. Constructions de proteine de liaison a l'antigene et utilisations de celles-ci
WO2021024020A1 (fr) 2019-08-06 2021-02-11 Astellas Pharma Inc. Polythérapie impliquant des anticorps dirigés contre la claudine 18.2 et inhibiteurs de point de contrôle immunitaire pour le traitement du cancer
US11896676B2 (en) 2019-08-07 2024-02-13 Case Western Reserve University Targeting cancer cells and tissue using filamentous plant virus particles
EP4069312A4 (fr) * 2019-12-04 2024-03-27 The Research Foundation for the State University of New York Compositions et procédés visant à réduire la toxicité hors cible de conjugués anticorps-médicament
US12203073B2 (en) 2019-12-20 2025-01-21 Case Western Reserve University Plant viral RNA delivery nanoparticles and uses thereof
US11529430B2 (en) 2019-12-20 2022-12-20 Case Western Reserve University Polydopamine decorated tobacco mosaic theranostic virus nanoparticles
US20250262293A1 (en) 2020-07-07 2025-08-21 BioNTech SE Therapeutic rna for hpv-positive cancer
WO2022135667A1 (fr) 2020-12-21 2022-06-30 BioNTech SE Arn thérapeutique pour le traitement du cancer
WO2022135666A1 (fr) 2020-12-21 2022-06-30 BioNTech SE Programme de traitement faisant intervenir des protéines cytokines
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
CN112724263B (zh) * 2021-04-02 2021-08-03 上海偌妥生物科技有限公司 改造抗cd20单克隆抗体以提高其药物疗效的方法及其应用
MX2024000674A (es) 2021-07-13 2024-02-07 BioNTech SE Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion.
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2022078524A2 (fr) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Conjugaison spécifique d'un anticorps
KR20240139082A (ko) 2022-02-02 2024-09-20 화이자 인코포레이티드 시스테인 프로토트로피
JPWO2024058201A1 (fr) * 2022-09-16 2024-03-21
IL320482A (en) 2022-10-25 2025-06-01 Peptomyc S L Combination therapy for cancer treatment
IL321098A (en) 2022-12-14 2025-07-01 Astellas Pharma Europe Bv Combination therapy including bispecific binding agents that bind to CLDN18.2- and CD3- and immune checkpoint inhibitors
WO2024218706A1 (fr) 2023-04-21 2024-10-24 Pfizer Inc. Cellules et cultures cellulaires améliorées
WO2024251846A1 (fr) 2023-06-07 2024-12-12 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Polythérapie avec des inhibiteurs de mek pour le traitement du cancer
EP4473974A1 (fr) 2023-06-07 2024-12-11 Peptomyc, S.L. Polythérapie avec omomyc et des inhibiteurs de kras pour le traitement du cancer
TW202502371A (zh) 2023-06-07 2025-01-16 瓦爾希伯倫私人腫瘤研究基金會 用於治療癌症的與ｂｒａｆ抑制劑的組合療法
KR20250043317A (ko) * 2023-09-21 2025-03-28 주식회사 피노바이오 운반체-약물 접합체 및 dnmt-1 저해제의 병용 요법
TW202541837A (zh) 2023-12-08 2025-11-01 日商安斯泰來製藥公司 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法
WO2025120866A1 (fr) 2023-12-08 2025-06-12 Astellas Pharma Inc. Polythérapie impliquant des agents de liaison bispécifiques se liant à cldn18.2 et cd3 et agents stabilisant ou augmentant l'expression de cldn18.2
WO2026033885A1 (fr) 2024-08-08 2026-02-12 Astellas Pharma Inc. Polythérapie faisant intervenir des agents de liaison bispécifiques se liant à cldn18.2 et cd3 et agents stabilisant ou augmentant l'expression de cldn18.2
WO2025120867A1 (fr) 2023-12-08 2025-06-12 Astellas Pharma Inc. Polythérapie impliquant des agents de liaison bispécifiques se liant à cldn18.2 et cd3 et anticorps anti-vegfr2

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US5037651A (en) 1987-01-30 1991-08-06 American Cyanamid Company Dihydro derivatives of LL-E33288 antibiotics
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5134075A (en) * 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU8221191A (en) 1990-06-27 1992-01-23 Princeton University Probes for detecting mutant p53
KR100240308B1 (ko) * 1991-03-06 2000-01-15 플레믹 크리스티안 인간화된단클론성항체및혼성단클론성항체
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5686072A (en) * 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5484892A (en) * 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5712474A (en) * 1993-09-29 1998-01-27 Canon Kabushiki Kaisha Image processing apparatus for correcting blurring of an image photographed by a video camera
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
CN1172502A (zh) 1994-08-12 1998-02-04 亿万遗传股份有限公司 17q连锁的乳房癌和卵巢癌易患性基因的体内突变和多态性
CA2195557C (fr) * 1994-08-12 2006-10-17 Shui-On Leung Immunoconjugues et anticorps de type humain specifiques contre des lymphomes malins a cellules b et des cellules leucemiques
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20020141990A1 (en) * 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
ATE383430T1 (de) 1997-03-20 2008-01-15 Us Gov Health & Human Serv Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
DK0999853T3 (da) 1997-06-13 2003-04-22 Genentech Inc Stabiliseret antostofformulering
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
US6183477B1 (en) * 1998-09-04 2001-02-06 Smith & Nephew, Inc. Attachment tool for drill guide
KR100345463B1 (ko) * 1998-11-19 2003-01-08 주)녹십자 B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
JP2000226336A (ja) * 1998-11-30 2000-08-15 Sankyo Co Ltd 免疫グロブリン製剤
DK1137941T4 (da) 1998-12-10 2014-01-06 Brystol Myers Squibb Company Protein-scaffolds til antistof-mimetika og andre bindingsproteiner
EP1194167B1 (fr) 1999-06-09 2009-08-19 Immunomedics, Inc. Immunotherapie de troubles auto-immuns a l'aide d'anticorps ciblant les cellules b
AU6558400A (en) * 1999-08-17 2001-03-13 Novo Nordisk A/S Stabilisation of freeze-dried cake
DE50001665D1 (de) * 1999-10-12 2003-05-08 Connex Ges Zur Optimierung Von Verbessertes verfahren zum nachweis von säure-resistenten bakterien der gattung helicobacter im stuhl
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
DK1507556T3 (en) 2002-05-02 2016-09-12 Wyeth Holdings Llc Calicheamicin derivative-carrier conjugates
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products

Also Published As

Publication number Publication date
NO344509B1 (no) 2020-01-20
SG10201700289RA (en) 2017-02-27
PL228741B1 (pl) 2018-05-30
RU2678818C2 (ru) 2019-02-04
RU2016141576A (ru) 2018-05-03
CN1665532A (zh) 2005-09-07
EP1507556A4 (fr) 2009-01-07
JP5153057B2 (ja) 2013-02-27
CY1116634T1 (el) 2017-03-15
PT2371392E (pt) 2015-10-07
ECSP045445A (es) 2005-01-28
HUE057124T2 (hu) 2022-04-28
DK2371392T3 (en) 2015-08-31
HUE030806T2 (hu) 2017-05-29
US20160303252A1 (en) 2016-10-20
PL224001B1 (pl) 2016-11-30
JP2017105801A (ja) 2017-06-15
CR20120364A (es) 2012-10-05
IL164946A0 (en) 2005-12-18
WO2003092623A3 (fr) 2004-03-18
HUS1700038I1 (hu) 2017-11-28
EP3127553A1 (fr) 2017-02-08
KR101062628B1 (ko) 2011-09-07
HK1162926A1 (en) 2012-09-07
PH12013501158A1 (en) 2015-11-09
AU2003231293A1 (en) 2003-11-17
LTPA2017036I1 (lt) 2017-11-27
PH12013501159A1 (en) 2015-12-02
NL300903I2 (nl) 2018-02-08
AU2009202609A1 (en) 2009-07-16
JP2015061875A (ja) 2015-04-02
BR122019027974B1 (pt) 2022-06-14
KR20050006220A (ko) 2005-01-15
BR122019027966B8 (pt) 2021-07-27
LUC00044I1 (fr) 2017-11-03
ES2916174T3 (es) 2022-06-28
JP5441971B2 (ja) 2014-03-12
BR122019027966B1 (pt) 2020-11-17
PL374523A1 (en) 2005-10-31
TW200404005A (en) 2004-03-16
IL164946A (en) 2015-06-30
PH12013501159B1 (en) 2015-12-02
US8835611B2 (en) 2014-09-16
SI2371392T1 (sl) 2015-10-30
HUE057124T4 (hu) 2022-02-28
EP3127553B1 (fr) 2021-12-01
PL410219A1 (pl) 2015-03-30
PL410218A1 (pl) 2015-03-30
JP2013163678A (ja) 2013-08-22
CN100482277C (zh) 2009-04-29
EP2371392A1 (fr) 2011-10-05
IL230659A (en) 2016-02-29
EP2371392B1 (fr) 2015-07-08
EP1507556A2 (fr) 2005-02-23
US20040192900A1 (en) 2004-09-30
EP1507556B1 (fr) 2016-07-27
CY1117973T1 (el) 2017-05-17
TW201231089A (en) 2012-08-01
NO2017061I1 (no) 2017-11-21
US8153768B2 (en) 2012-04-10
KR20110050753A (ko) 2011-05-16
ZA201003874B (en) 2019-12-18
ZA200409752B (en) 2010-08-25
CR7557A (es) 2008-10-03
US20120213804A1 (en) 2012-08-23
NZ573563A (en) 2010-10-29
CR20130390A (es) 2013-11-08
RU2004135101A (ru) 2005-06-27
ES2593304T3 (es) 2016-12-07
CA2871117A1 (fr) 2003-11-13
DK1507556T3 (en) 2016-09-12
PL413302A1 (pl) 2016-05-23
NO339730B1 (no) 2017-01-23
TWI379693B (en) 2012-12-21
FR17C1054I1 (fr) 2018-01-12
NO20044663L (no) 2005-01-25
RU2602878C3 (ru) 2021-11-24
US8747857B2 (en) 2014-06-10
RU2422157C3 (ru) 2021-04-23
US9351986B2 (en) 2016-05-31
PT3127553T (pt) 2022-01-24
RU2016141576A3 (fr) 2018-05-03
HUE027590T2 (hu) 2016-11-28
BR0309868A (pt) 2005-10-18
JP5756489B2 (ja) 2015-07-29
WO2003092623A2 (fr) 2003-11-13
DK3127553T3 (da) 2022-01-31
ES2545745T3 (es) 2015-09-15
SI3127553T1 (sl) 2022-02-28
LTC2371392I2 (lt) 2019-03-25
JP6872376B2 (ja) 2021-05-19
US20180339058A1 (en) 2018-11-29
SI1507556T1 (sl) 2016-10-28
NZ586071A (en) 2012-02-24
MXPA04010792A (es) 2005-03-07
PT1507556T (pt) 2016-09-28
LT3127553T (lt) 2022-04-11
FR17C1054I2 (fr) 2019-01-11
PL411824A1 (pl) 2015-08-17
PL224844B1 (pl) 2017-02-28
RU2602878C2 (ru) 2016-11-20
BRPI0309868B1 (pt) 2020-04-28
CA2483552A1 (fr) 2003-11-13
BRPI0309868B8 (pt) 2021-05-25
UA88599C2 (ru) 2009-11-10
RU2011108928A (ru) 2012-09-20
CY2017035I1 (el) 2018-04-04
PL224150B1 (pl) 2016-11-30
IL230659A0 (en) 2014-03-31
RU2422157C2 (ru) 2011-06-27
US20040082764A1 (en) 2004-04-29
LUC00044I2 (fr) 2018-02-26
KR101125524B1 (ko) 2012-03-22
SG187991A1 (en) 2013-03-28
CY1124900T1 (el) 2023-01-05
NO20161431A1 (no) 2005-01-25
CY2017035I2 (el) 2018-04-04
JP2005524700A (ja) 2005-08-18
SG165158A1 (en) 2010-10-28
US20140235835A1 (en) 2014-08-21
LT1507556T (lt) 2016-10-10
AU2009202609B2 (en) 2012-07-26
JP2012051900A (ja) 2012-03-15
HK1070825A1 (en) 2005-06-30
PL222725B1 (pl) 2016-08-31
TWI438010B (zh) 2014-05-21
PH12013501158B1 (en) 2015-11-09

Similar Documents

Publication Publication Date Title
LUC00044I2 (fr)
BE2016C040I2 (fr)
BE2015C017I2 (fr)
BE2014C053I2 (fr)
BE2014C051I2 (fr)
BE2014C041I2 (fr)
BE2014C030I2 (fr)
BE2014C016I2 (fr)
BE2014C015I2 (fr)
BE2013C063I2 (fr)
BE2013C039I2 (fr)
BE2011C038I2 (fr)
JP2003198604A5 (fr)
BE2015C068I2 (fr)
IN192749B (fr)
BE2013C046I2 (fr)
DE60330807D1 (fr)
JP2003056473A5 (fr)
DE60333727D1 (fr)
HU0202032D0 (fr)
JP2003232859A5 (fr)
JP2003208898A5 (fr)
JP2002224360A5 (fr)
AU2002226740A1 (fr)
AU2001279184A1 (fr)